Evidence map›Paper›PMID 11959793›Full record

ArticleBritish journal of pharmacology2002

Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways.

Dana S Hutchinson, Tore Bengtsson, Bronwyn A Evans, Roger J Summers

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The metabolic effects of mirabegron are mediated primarily by βPharmacology research & perspectives · 2020
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. β(3) Receptors: Role in Cardiometabolic Disorders.Therapeutic advances in endocrinology and metabolism · 2011
    Article
  15. Article
  16. Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.Journal of molecular and cellular cardiology · 2010
    Review
  17. Ligand-directed signalling at beta-adrenoceptors.British journal of pharmacology · 2010
    Review
  18. Article
  19. Tools to study beta3-adrenoceptors.Naunyn-Schmiedeberg's archives of pharmacology · 2007
    Review
  20. Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor.Naunyn-Schmiedeberg's archives of pharmacology · 2006
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Dana S HutchinsonDepartment of Pharmacology, P.O. Box 13E, Monash University, Victoria 3800, Australia.
Tore Bengtsson
Bronwyn A Evans
Roger J Summers
Monash University · AUStockholm University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1. This study characterizes the mouse beta(3a)-adrenoceptor (AR) and the splice variant of the beta(3)-AR (beta(3b)-AR) expressed in Chinese hamster ovary cells (CHO-K1). 2. Stable clones with high (approximately 1200), medium (approximately 500) or low receptor expression (approximately 100 fmol mg protein(-1)) were determined by saturation binding with [(125)I]-(-)-cyanopindolol. Competition binding studies showed no significant differences in affinity of beta-AR ligands for either receptor. 3. Several functional responses of each receptor were measured, namely extracellular acidification rate (EAR; cytosensor microphysiometer), cyclic AMP accumulation, and Erk1/2 phosphorylation. The beta(3)-AR agonists BRL37344, CL316243, GR265162X, L755507, SB251023, the non-conventional partial beta-AR agonist CGP12177 and the beta-AR agonist (-)-isoprenaline caused concentration-dependent increases in EAR in cells expressing either splice variant. CL316243 caused concentration-dependent increases in cyclic AMP accumulation and Erk1/2 phosphorylation in cells expressing either receptor. 4. PTX treatment increased maximum EAR and cyclic AMP responses to CL316243 in cells expressing the beta(3b)-AR but not in cells expressing the beta(3a)-AR at all levels of receptor expression. 5. CL316243 increased Erk1/2 phosphorylation with pEC(50) values and maximum responses that were not significantly different in cells expressing either splice variant. Erk1/2 phosphorylation was insensitive to PTX or H89 (PKA inhibitor) but was inhibited by LY294002 (PI3K gamma inhibitor), PP2 (c-Src inhibitor), genistein (tyrosine kinase inhibitor) and PD98059 (MEK inhibitor). 6. The adenylate cyclase activators forskolin or cholera toxin failed to increase Erk1/2 levels although both treatments markedly increased cyclic AMP accumulation in both beta(3a)- or beta(3b)-AR transfected cells. 7. These results suggest that in CHO-K1 cells, the beta(3b)-AR, can couple to both G(s) and G(i) to stimulate and inhibit cyclic AMP production respectively, while the beta(3a)-AR, couples solely to G(s) to increase cyclic AMP levels. However, the increase in Erk1/2 phosphorylation following receptor activation is not dependent upon coupling of the receptors to G(i) or the generation of cyclic AMP.

Indexed as

Adrenergic beta-3 Receptor AgonistsAdrenergic beta-3 Receptor AntagonistsAdrenergic beta-AgonistsAdrenergic beta-AntagonistsAmino Acid SequenceAnimalsCHO CellsCricetinaeCyclic AMPDioxolesDose-Response Relationship, DrugMiceMitogen-Activated Protein KinasesMolecular Sequence DataProtein IsoformsReceptors, Adrenergic, beta-3Adrenergic beta-3 Receptor AgonistsAdrenergic beta-3 Receptor AntagonistsAdrenergic beta-AgonistsAdrenergic beta-AntagonistsCyclic AMPDioxolesdisodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylateMitogen-Activated Protein KinasesProtein IsoformsReceptors, Adrenergic, beta-3

Identifiers

PMID11959793
PMCPMC1573318
OpenAlexW2088812635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.